Validation and digital implementation of the HADES score for hereditary angioedema
Frontiers in Epidemiology · 12.11.2026 · 6
DOI: 10.3389/fepid.2026.2000978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Epidemiology, online erschienen am 12.11.2026. Verfasst von Ricardo Dario Zwiener und 6 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Background
Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is frequently misdiagnosed, leading to delayed diagnosis and inappropriate management. We previously developed a predictive clinical score (HADES) to support early identification of patients at risk for HAE-C1-INH.
Objective
To evaluate the temporal performance of HADES in a new cohort of patients with suspected HAE-C1-INH and explore the feasibility of its digital implementation in a small prospective pilot study.
Methods
A total of 539 individuals with suspicion of HAE-C1-INH were evaluated. HADES scores were calculated using the previously predefined thresholds, and diagnostic performance and ROC analyses were compared with the derivation cohort. In parallel, a prospective pilot study using the HADES App was conducted in 18 patients to assess its implementation feasibility. In addition, 6 patients with HAE-FXII were analyzed separately for exploratory purposes.
Results
The validation cohort reproduced key performance characteristics of the original model. Sensitivity remained 100% at low thresholds, specificity increased across score categories, and no confirmed HAE-C1-INH cases occurred in score category 0. The AUC was 0.80 (95% CI, 0.73-0.86), matching the derivation dataset. The exploratory HADES-App cohort provided preliminary information on digital implementation feasibility. Patients with HAE- FXII showed score distributions overlapping those of HAE-C1-INH cases.
Conclusion
In a temporal validation cohort, HADES demonstrated discriminative performance consistent with the original study and reasonable overall category-level calibration, supporting its potential role as a clinical screening tool for HAE-C1-INH. Preliminary digital implementation findings warrant further prospective evaluation.
Förderung
- Takeda Pharmaceutical Company
Zitieren
APA
Zwiener, R. D., Labrador, L. C., Zamora, R., Galmarini, C. M., Brion, L., Pino, A., & Rozenfeld, P. (2026). Validation and digital implementation of the HADES score for hereditary angioedema. Frontiers in Epidemiology, 6. https://doi.org/10.3389/fepid.2026.2000978
Vancouver
Zwiener RD, Labrador LC, Zamora R, Galmarini CM, Brion L, Pino A, et al. Validation and digital implementation of the HADES score for hereditary angioedema. Frontiers in Epidemiology. 2026;6. doi:10.3389/fepid.2026.2000978
BibTeX
@article{Zwiener2026,
author = {Zwiener, Ricardo Dario and Labrador, Laura Castro and Zamora, Rafael and Galmarini, Carlos María and Brion, Laura and Pino, Andrea and Rozenfeld, Paula},
title = {Validation and digital implementation of the HADES score for hereditary angioedema},
journal = {Frontiers in Epidemiology},
year = {2026},
volume = {6},
doi = {10.3389/fepid.2026.2000978}
}
EUVIMED